股份回购与注销

Search documents
九号公司: 九号有限公司关于调整回购股份用途并注销的公告
Zheng Quan Zhi Xing· 2025-08-01 16:35
Core Viewpoint - The company plans to adjust the purpose of repurchased shares from employee stock ownership plans to cancellation, aiming to enhance shareholder value and maintain investor confidence [1][5]. Summary by Sections 1. Basic Information on Share Repurchase - The company approved a share repurchase plan on January 10, 2024, with a total repurchase amount between RMB 300 million and RMB 500 million, at a maximum price of RMB 58 per share, within a 12-month period [1][2]. 2. Adjustment of Share Repurchase Purpose - The company intends to adjust the use of 6,000,000 shares from the repurchase account, changing it from "for employee stock ownership plans" to "for cancellation" [1][3]. 3. Changes in Total Depository Receipts - After the cancellation of 6,000,000 shares, the total number of depository receipts will decrease from 719,444,662 to 713,444,662 [4]. 4. Reasons and Impacts of the Adjustment - The decision is based on the company's operational situation and strategic planning, aiming to enhance returns for depository receipt holders without negatively impacting the company's financial status or debt obligations [5]. 5. Decision-Making Process - The adjustment has been approved by the company's board and will be submitted for shareholder approval, ensuring compliance with relevant laws and regulations [5].
振德医疗: 振德医疗关于变更部分回购股份用途并注销的公告
Zheng Quan Zhi Xing· 2025-07-23 16:23
Core Viewpoint - The company plans to change the purpose of repurchased shares from "for employee stock ownership plan" to "cancel and reduce registered capital" for 615,667 shares, which represents 0.23% of the total share capital [1][2][4]. Summary by Sections Share Repurchase Implementation - The company approved a share repurchase plan on December 31, 2020, with a total fund of no less than RMB 120 million and no more than RMB 160 million, to be completed within 12 months [2]. - The repurchase price was capped at RMB 72.00 per share, with a total transaction amount of RMB 12 million [2]. Change of Purpose and Cancellation - The board of directors agreed to change the purpose of the repurchased shares from "for employee stock ownership plan" to "cancel and reduce registered capital" due to the failure to unlock shares in the first employee stock ownership plan [3][4]. - After the cancellation, the total share capital will decrease from 266,451,202 shares to 265,835,535 shares, and registered capital will reduce from RMB 266,451,202 to RMB 265,835,535 [1][4]. Impact of the Change - The change in the purpose of repurchased shares and cancellation is expected to have no significant impact on the company's financial status or operational results, nor will it affect the company's debt repayment ability or ongoing operations [5][6]. - The company maintains that this decision does not harm the interests of shareholders, especially minority shareholders, and will not lead to changes in the controlling shareholder or actual controller [6]. Decision-Making Process - The decision was made during the 22nd meeting of the third board of directors and the 19th meeting of the third supervisory board on July 23, 2025, and requires approval from the shareholders' meeting [6][7]. - The supervisory board supports the decision, confirming that it complies with relevant regulations and does not harm the interests of the company or its shareholders [7].
亿嘉和: 亿嘉和科技股份有限公司2025年第二次临时股东大会会议资料
Zheng Quan Zhi Xing· 2025-07-17 10:22
Core Viewpoint - The company is holding its second extraordinary general meeting of shareholders in 2025 to discuss important matters including share repurchase, cancellation of the supervisory board, and the appointment of the auditing firm for the fiscal year 2025 [2][7][11]. Group 1: Shareholder Meeting Procedures - The meeting aims to maintain the legal rights of all shareholders and ensure orderly proceedings [2]. - Only authorized personnel, including shareholders, directors, supervisors, and invited guests, are allowed to attend the meeting [3]. - Late attendees can participate in discussions but cannot vote if they arrive after voting has commenced [3][4]. - Shareholders have the right to speak, inquire, and vote during the meeting, with specific procedures for raising questions and making statements [5][6]. Group 2: Share Repurchase and Capital Reduction - The company approved a share repurchase plan in May 2022, allocating between RMB 50 million and RMB 100 million for repurchasing shares at a maximum price of RMB 69 per share [7][15]. - As of August 16, 2022, the company repurchased a total of 960,396 shares, representing a certain percentage of the total share capital [7][15]. - The company plans to cancel these repurchased shares, reducing the total share capital from 206,490,816 shares to 205,530,420 shares, and the registered capital from RMB 20,649,081.6 to RMB 20,553,042.0 [10][15]. Group 3: Governance Changes - The company proposes to abolish the supervisory board, transferring its responsibilities to the audit committee of the board of directors, in line with new regulations effective from July 1, 2024 [11][12]. - The company will revise its articles of association and related governance documents to reflect these changes [14][17]. - The proposed changes aim to enhance corporate governance and protect the interests of investors, particularly minority shareholders [17]. Group 4: Auditing Firm Appointment - The company recommends reappointing Tianheng Accounting Firm for the 2025 fiscal year, maintaining the audit fee at RMB 1.16 million, consistent with the previous year [12][13]. - The firm has demonstrated the necessary qualifications and experience in providing auditing services to listed companies [12]. Group 5: Other Proposals - The company will revise its internal regulations to improve operational standards and governance structures [17]. - The revisions will be comprehensive, addressing various aspects of corporate governance in accordance with relevant laws and regulations [17].
康恩贝: 关于注销回购股份实施结果暨股份变动公告
Zheng Quan Zhi Xing· 2025-07-08 16:19
Buyback Approval and Plan - The board of directors approved a share buyback plan using self-owned funds through centralized bidding on January 23, 2024, with a total fund amount between 200 million yuan and 400 million yuan, and a maximum buyback price of 7 yuan per share [1] Buyback Implementation - The company initiated its first share buyback on January 29, 2024, and completed the buyback by July 21, 2024, acquiring 63.579048 million shares, which is 2.47% of the total share capital at that time. The highest buyback price was 5.00 yuan per share, the lowest was 4.08 yuan, and the average price was 4.72 yuan, with a total expenditure of approximately 299.9241 million yuan [2][3] Use of Funds and Impact - The funds used for the buyback were from the company's own resources and did not significantly impact its daily operations, financial status, or future development. The buyback did not alter the company's control or affect its listing status [3] Shareholder Trading Activity - During the buyback period, company directors, supervisors, and senior management did not trade company shares, except for the controlling shareholder, Zhejiang Pharmaceutical Health Industry Group, which planned to increase its stake by 2% to 4% of the total share capital [3] Change in Buyback Share Purpose - The purpose of the repurchased shares was changed from "for equity incentives" to "for cancellation to reduce registered capital" as approved in board meetings held on April 23 and May 2025 [3] Cancellation of Repurchased Shares - The company announced a notification to creditors regarding the cancellation of repurchased shares, with a creditor declaration period from May 24 to July 7, 2025. No creditors requested early debt repayment or guarantees during this period [5] Post-Cancellation Share Capital Changes - After the cancellation of shares, the total share capital will decrease from 2,585,167,996 shares to 2,521,588,948 shares, reflecting a change in ownership percentages among shareholders [6] Shareholder Ownership Changes - Following the cancellation, the controlling shareholder, Zhejiang Pharmaceutical Health Industry Group, maintained its shareholding at 594,209,740 shares, increasing its ownership percentage from 22.99% to 23.56% [6]
金证股份: 金证股份2025年第二次临时股东会会议资料
Zheng Quan Zhi Xing· 2025-06-20 09:22
Group 1 - The company plans to change the purpose of the repurchased shares from "selling through centralized bidding" to "cancellation and reduction of registered capital" [1][2] - A total of 5,007,526 shares, which is 0.53% of the company's total share capital, will be canceled and the registered capital will decrease from 946,275,005 yuan to 941,267,479 yuan [2] - The board of directors requests authorization from the shareholders' meeting for the management to handle the cancellation and related procedures [2] Group 2 - The repurchase of shares was conducted from June 1, 2022, to May 30, 2025, with 5,000,000 shares sold during this period, representing 0.53% of the total share capital [1] - The change in the purpose of the repurchased shares is aligned with the company's operational situation and development strategy, aimed at enhancing shareholder value and investor confidence [1][2] - The cancellation of the shares will not significantly impact the company's financial status, operational results, or shareholder equity, nor will it affect the company's listing status [2]
航锦科技股份有限公司 关于回购股份注销完成暨股份变动的公告
Zhong Guo Zheng Quan Bao - Zhong Zheng Wang· 2025-06-06 00:39
Core Viewpoint - The company has completed the repurchase and cancellation of shares, reflecting confidence in its future development and value recognition [3][5][6] Group 1: Share Repurchase Details - The company approved a share repurchase plan on February 23, 2024, with a total fund of no less than RMB 30 million and no more than RMB 40 million, at a maximum price of RMB 37.95 per share [3][5] - The actual repurchase period was from March 26, 2024, to December 31, 2024, during which 19,155,961 shares were repurchased, accounting for 2.82% of the total share capital before cancellation [5][6] - The highest transaction price during the repurchase was RMB 30.15 per share, while the lowest was RMB 14.07 per share, with a total transaction amount of approximately RMB 391.67 million [5] Group 2: Cancellation of Shares - The cancellation of the repurchased shares was completed on June 4, 2025, in compliance with relevant laws and regulations [4][6] - The number of shares canceled was 19,155,961, which represented 2.82% of the total share capital prior to cancellation [6] Group 3: Impact on the Company - The share repurchase is based on the company's confidence in its future prospects and will not adversely affect its operations, finances, research and development, or debt obligations [6] - The completion of the repurchase will not impact the company's listing status or control structure [6]
三星医疗: 三星医疗关于变更回购股份用途并注销的公告
Zheng Quan Zhi Xing· 2025-05-28 10:44
Core Viewpoint - The company plans to change the purpose of repurchased shares from employee stock ownership plans to cancellation and reduction of registered capital, involving 5,755,371 shares, which is approximately 0.41% of the total share capital [1][2][3]. Group 1: Share Repurchase Details - The company approved a share repurchase plan on December 7, 2023, with a total repurchase amount between RMB 150 million and RMB 300 million, at a price not exceeding RMB 21.00 per share [2]. - The company has completed the repurchase of shares at an average price of RMB 19.30 per share, totaling RMB 279,083,618.90, and has used 2,048,590 shares for its core team stock ownership plan [3]. Group 2: Purpose Change and Cancellation - The purpose of the repurchased shares is being changed to cancellation and reduction of registered capital, which will leave a balance of 5,755,371 shares in the repurchase account after the cancellation [3][5]. - Following the cancellation, the total share capital will decrease from 1,411,006,571 shares to 1,405,251,200 shares, and the registered capital will similarly decrease from RMB 1,411,006,571 to RMB 1,405,251,200 [1][4]. Group 3: Impact and Compliance - The change in the purpose of repurchased shares aligns with relevant laws and regulations, reflecting the company's confidence in future development and long-term value [5]. - This action is expected to optimize shareholder returns and enhance investor confidence without significantly impacting the company's financial status or operational capabilities [5].
荣盛石化股份有限公司
Shang Hai Zheng Quan Bao· 2025-04-25 03:18
登录新浪财经APP 搜索【信披】查看更多考评等级 付款方式:电子转账 协议有效期:按签署协议执行 3.向恒逸贸易采购PTA等产品 公司拟与恒逸贸易签订购销合同,主要内容如下: 供方:恒逸贸易(包括其下属公司) 需方:荣盛石化(包括其下属公司) 交易内容:需方向供方采购PTA等产品 交易定价:以PTA等产品报结价为准 付款方式:银行承兑汇票、现汇或信用证 协议有效期:按签署协议执行 4.向恒逸贸易销售PX、聚丙烯等产品 公司拟与恒逸贸易签订购销合同,主要内容如下: 供方:荣盛石化(包括其下属公司) 需方:恒逸贸易(包括其下属公司) 交易内容:供方向需方销售PX、聚丙烯等产品 交易定价:以PX、聚丙烯等产品报结价为准 付款方式:银行承兑汇票、现汇或信用证 协议有效期:按签署协议执行 5.向海南逸盛采购PTA等产品 公司拟与海南逸盛签订购销合同,主要内容如下: 供方:海南逸盛(包括其下属公司) 需方:荣盛石化(包括其下属公司) 交易内容:需方向供方采购PTA等产品 交易定价:以PTA等产品报结价为准 付款方式:银行承兑汇票、现汇或信用证 协议有效期:按签署协议执行 6.向浙江逸盛采购PIA、PX、冰醋酸等产品 公司 ...
大族激光: 关于变更回购股份用途并注销的公告
Zheng Quan Zhi Xing· 2025-04-02 11:02
Core Viewpoint - The company, Dazong Laser Technology Industry Group Co., Ltd., plans to change the purpose of its repurchased shares from employee stock ownership plans and maintaining shareholder value to cancellation for reducing registered capital [1][2]. Summary by Sections 1. Basic Information on Share Repurchase - The company approved a share repurchase plan on February 2, 2024, with a budget of between RMB 500 million and RMB 1 billion, at a price not exceeding RMB 25 per share [1]. - A total of 22,589,592 shares were repurchased, accounting for 2.15% of the total share capital, with the highest transaction price at RMB 24.96 and the lowest at RMB 15.41 [2]. 2. Reasons for Changing the Purpose of Share Repurchase - The decision aligns with regulatory guidelines encouraging companies to cancel repurchased shares to protect investor interests and enhance long-term investment value [2][3]. - The change is based on the company's operational status and strategic planning, aiming to improve per-share equity and boost investor confidence [2]. 3. Impact of the Change on Company Shares - Following the cancellation, the total share capital will decrease from 1,052,193,000 shares to 1,029,603,408 shares [2]. - The share structure will adjust, with limited sale condition shares remaining at 72,876,026 (7.08%) and unrestricted shares decreasing to 956,727,382 (92.92%) [2]. 4. Procedures for Implementing the Change - The change requires approval from the shareholders' meeting and must comply with relevant legal and regulatory procedures [3]. - The board will seek authorization from shareholders to proceed with the cancellation and necessary registrations [3].